Description

Tesamorelin is a modified 44-amino-acid peptide, structurally based on human growth hormone-releasing hormone (GHRH), designed to promote endogenous growth hormone (GH) secretion by acting directly on pituitary somatotrophs. It has enhanced stability and resistance to enzymatic degradation, resulting in prolonged biological activity compared to native GHRH.

Tesamorelin has been extensively studied for its ability to reduce visceral adipose tissue and improve lipid profiles, particularly in individuals with altered fat distribution. Research has demonstrated its efficacy in stimulating IGF-1 production, enhancing lipolysis, and supporting protein metabolism without significantly altering glucose homeostasis.

Due to its physiological stimulation of GH release, Tesamorelin is also investigated in studies related to age-related hormonal decline, metabolic syndrome, muscle maintenance, and cardiovascular risk factors. Its targeted mechanism and favorable safety profile make it a key compound in clinical and experimental research focused on hormonal balance and body composition optimization.